The management of hepatocellular carcinoma around the world: A comparison of guidelines from 2001 to 2011

Liver International

Volumn 32, Issue 7, 2012, Pages 1053-1063

  Song, Peipei ^a   Tobe, Ruoyan G ^a   Inagaki, Yoshinori ^a   Kokudo, Norihiro ^a   Hasegawa, Kiyoshi ^a   Sugawara, Yasuhiko ^a   Tang, Wei ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Clinical guideline; Establishing and implementing; Evaluation; Hepatocellular carcinoma (HCC)

Indexed keywords

SORAFENIB;

ALGORITHM; CANCER MORTALITY; CANCER SCREENING; CANCER SURVIVAL; CLINICAL PRACTICE; COMPARATIVE STUDY; DIAGNOSTIC ACCURACY; DRUG EFFICACY; HEPATITIS B; HEPATITIS C; HUMAN; LIVER CELL CARCINOMA; MEDICAL DECISION MAKING; PATIENT CARE; PATIENT COMPLIANCE; PRACTICE GUIDELINE; REVIEW; RISK FACTOR; SURVIVAL RATE; TREATMENT OUTCOME;

CARCINOMA, HEPATOCELLULAR; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH CARE COSTS; HUMANS; LIVER NEOPLASMS; MALE; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84863509612     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2012.02792.x     Document Type: Review

References (76)

1. American Cancer Society. Cancer facts and figs 2005. Available:. Accessed 6 February 2011.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 2007; 132: 2557-76.
3. International Agency for Research on Cancer. Cancer incidence and mortality worldwide in 2008 (GLOBOCAN 2008). Available:. Accessed 5 February 2011.
4. Lopez PM, Villanueva A, Llovet JM. Systematic review: evidence-based management of hepatocellular carcinoma - an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 2006; 23: 1535-47.
5. Abbadessa G, Rimassa L, Pressiani T, et al. Optimized management of advanced hepatocellular carcinoma: four long-lasting responses to sorafenib. World J Gastroenterol 2011; 17: 2450-3.
6. Lencioni R, Chen XP, Dagher L, Venook AP. Treatment of intermediate/advanced hepatocellular carcinoma in the clinic: how can outcomes be improved? Oncologist 2010; 15: 42-52.
7. Field MJ, Lohr KN (eds). Clinical Practice Guidelines: Directions for a New Program. Washington, DC: National Academy Press, 1990.
8. Pavlidis N, Hansen H, Stahel R. ESMO clinical recommendations: a practical guide for medical oncologists. Ann Oncol 2007; 18: 1759-63.
9. Farquhar CM, Kofa EW, Slutsky JR. Clinicians' attitudes to clinical practice guidelines: a systematic review. Med J Aust 2002; 177: 502-6.
10. Varga D, Wischnewsky M, Atassi Z, et al. Does guideline-adherent therapy improve the outcome for early-onset breast cancer patients? Oncology 2010; 78: 189-95.
11. Bruix J, Sherman M, Llovet JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. J Hepatol 2001; 35: 421-30.
12. Group formed to establish "guidelines for evidence-based clinical practice for the treatment of liver cancer". Clinical practice guidelines for hepatocellular carcinoma. Tokyo, Japan: Kanehara Press, 2005. (in Japanese).
13. Omata M, Lesmana LA, Tateishi R, et al. Asian Pacific Association for the study of the liver consensus recommendations on hepatocellular carcinoma. Hepatol Int 2010; 4: 439-74.
14. Ryder SD, British Society of Gastroenterology. Guidelines for the diagnosis and treatment of hepatocellular carcinoma (HCC) in adults. Gut 2003; 52: iii1-8.
15. Benson AB 3rd, Abrams TA, Ben-Josef E, et al. NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw 2009; 7: 350-91.
16. Lau WY, Lai EC. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreat Dis Int 2008; 7: 237-57.
17. Colli A, Fraquelli M, Casazza G, et al. Accuracy of ultrasonography, spiral CT, magnetic resonance, and alpha-fetoprotein in diagnosing hepatocellular carcinoma: a systematic review. Am J Gastroenterol 2006; 101: 513-23.
18. Marrero JA. Screening tests for hepatocellular carcinoma. Clin Liver Dis 2005; 9: 235-51.
19. Nazir RT, Sharif MA, Iqbal M, Amin MS. Diagnostic accuracy of fine needle aspiration cytology in hepatic tumours. J Coll Physicians Surg Pak 2010; 20: 373-6.
20. Silva MA, Hegab B, Hyde C, et al. Needle track seeding following biopsy of liver lesions in the diagnosis of hepatocellular cancer: a systematic review and meta-analysis. Gut 2008; 57: 1592-6.
21. Parikh P, Malhotra H, Jelic S, ESMO Guidelines Working Group. Hepatocellular carcinoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2008; 19: ii27-8.
22. Van Vlierberghe H, Borbath I, Delwaide J, et al. BASL guidelines for the surveillance, diagnosis and treatment of hepatocellular carcinoma. Acta Gastroenterol Belg 2004; 67: 14-25.
23. Abdo AA, Karim HA, Al Fuhaid T, et al. Saudi Gastroenterology Association guidelines for the diagnosis and management of hepatocellular carcinoma: summary of recommendations. Ann Saudi Med 2006; 26: 261-5.
24. Bruix J, Sherman M, Practice Guidelines Committee, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma. Hepatology 2005; 42: 1208-36.
25. Park JW, Korean Liver Cancer Study Group and National Cancer Center. Practice guideline for diagnosis and treatment of hepatocellular carcinoma. Korean J Hepatol 2004; 10: 88-98. (in Korean).
26. Expert Panel of Japan Society of Hepatology. Clinical Practice Manual for Hepatocellular Carcinoma. Tokyo, Japan: Igaku-Shoin, 2007. (in Japanese).
27. Poon D, Anderson BO, Chen LT, et al. Management of hepatocellular carcinoma in Asia: consensus statement from the Asian Oncology Summit 2009. Lancet Oncol 2009; 10: 1111-8.
28. Ishida H, Matsuo S, Inoue Y. Evaluation of diagnostic performance of alpha-fetoprotein (AFP) and des-gamma-carboxy prothrombin (DCP) for HCV related hepatocellular carcinoma developed after long-term follow up. Rinsho Byori 2010; 58: 1065-72. (in Japanese).
29. Nomura F, Ishijima M, Kuwa K, et al. Serum desgamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 650-4.
30. Inagaki Y, Tang W, Makuuchi M, et al. Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int 2011; 31: 22-35.
31. Inagaki Y, Tang W, Xu H, et al. Des-γ-carboxyprothrombin: clinical effectiveness and biochemical importance. BioSci Trends 2008; 2: 53-60.
32. Wong R, Frenette C. Updates in the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2011; 7: 16-24.
33. Rahbari NN, Mehrabi A, Mollberg NM, et al. Hepatocellular carcinoma: current management and perspectives for the future. Ann Surg 2011; 253: 453-69.
34. Gish RG, Marrero JA, Benson AB. A multidisciplinary approach to the management of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) 2010; 6: 1-14.
35. Schwartz M, Roayaie S, Konstadoulakis M. Strategies for the management of hepatocellular carcinoma. Nat Clin Pract Oncol 2007; 4: 424-32.
36. Ferenci P, Fried M, Labrecque D, et al. World Gastroenterology Organization. Hepatocellular carcinoma (HCC): a global perspective. J Clin Gastroenterol 2010; 44: 239-45.
37. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma - The Japan Society of Hepatology 2009 update. Hepatol Res 2010; 40(Suppl. 1): 2-144.
38. Izumi N. Diagnostic and treatment algorithm of the Japanese society of hepatology: a consensus-based practice guideline. Oncology 2010; 78(Suppl. 1): 78-86.
39. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: a retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-9.
40. Nathan H, Schulick RD, Choti MA, Pawlik TM. Predictors of survival after resection of early hepatocellular carcinoma. Ann Surg 2009; 249: 799-805.
41. Poon RT, Fan ST, Ng IO, Wong J. Significance of resection margin in hepatectomy for hepatocellular carcinoma: a critical reappraisal. Ann Surg 2000; 231: 544-51.
42. Llovet JM, Fuster J, Bruix J, Barcelona-Clínic Liver Cancer Group. The Barcelona approach: diagnosis, staging, and treatment of hepatocellular carcinoma. Liver Transpl 2004; 10(Suppl. 1): S115-20.
43. Schwartz JD, Schwartz M, Mandeli J, Sung M. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 2002; 3: 593-603.
44. Llovet JM, Fuster J, Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 1999; 30: 1434-40.
45. Bismuth H, Majno PE, Adam R. Liver transplantation for hepatocellular carcinoma. Semin Liver Dis 1999; 19: 311-22.
46. Giglia JL, Antonia SJ, Berk LB, et al. Systemic therapy for advanced hepatocellular carcinoma: past, present, and future. Cancer Control 2010; 17: 120-9.
47. Kudo M. The 2008 Okuda lecture: management of hepatocellular carcinoma: from surveillance to molecular targeted therapy. J Gastroenterol Hepatol 2010; 25: 439-52.
48. Hoshida Y, Toffanin S, Lachenmayer A, et al. Molecular classification and novel targets in hepatocellular carcinoma: recent advancements. Semin Liver Dis 2010; 30: 35-51.
49. Chinese Anti-Cancer Association Society of Liver Cancer, Chinese Society of Clinical Oncology, Chinese Society of Hepatology Liver Cancer Study Group. The expert consensus on the treatment standards for hepatocellular carcinoma. Digestive Disease and Endoscopy 2009; 3: 40-51. (in Chinese).
50. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359: 378-90.
51. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009; 10: 25-34.
52. Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology 2011; 53: 1020-2.
53. Park JW. Hepatocellular carcinoma in Korea: introduction and overview. Korean J Gastroenterol 2005; 45: 217-26. (in Korean).
54. Chalasani N, Said A, Ness R, Hoen H, Lumeng L. Screening for hepatocellular carcinoma in patients with cirrhosis in the United States: results of a national survey. Am J Gastroenterol 1999; 94: 2224-9.
55. Korean Liver Cancer Study Group and National Cancer Center, Korea. Practice guidelines for management of hepatocellular carcinoma 2009. Korean J Hepatol 2009; 15: 391-423. (in Korean).
56. Cabrera R, Nelson DR. Review article: the management of hepatocellular carcinoma. Aliment Pharmacol Ther 2010; 31: 461-76.
57. Owen-Smith A, Coast J, Donovan J. The usefulness of NICE guidance in practice: different perspectives of managers, clinicians, and patients. Int J Technol Assess Health Care 2010; 26: 317-22.
58. Kokudo N, Sasaki Y, Nakayama T, Makuuchi M. Dissemination of evidence-based clinical practiceguidelines for hepatocellular carcinoma among Japanese hepatologists, liver surgeons and primary care physicians. Gut 2007; 56: 1020-1.
59. Sharma P, Saini SD, Kuhn LB, et al. Knowledge of hepatocellular carcinoma screening guidelines and clinical practices among gastroenterologists. Dig Dis Sci 2011; 56: 569-77.
60. Makuuchi M, Kokudo N. Clinical practice guidelines for hepatocellular carcinoma: the first evidence-based guidelines from Japan. World J Gastroenterol 2006; 12: 828-9.
61. Makuuchi M, Kokudo N, Arii S, et al. Development of evidence-based clinical guidelines for the diagnosis and treatment of hepatocellular carcinoma in Japan. Hepatol Res 2008; 38: 37-51.
62. ™. Available:. Accessed 6 March 2011.
63. National Institute for Health and Clinical Excellence. NICE guidance for patients and the public. Available:. Accessed 8 March 2011.
64. Jazieh AR, Azim HA, McClure J, Jahanzeb M. The process of NCCN guidelines adaptation to the Middle East and North Africa region. J Natl Compr Canc Netw 2010; 8(Suppl. 3): S5-7.
65. Theodoropoulos J, Brooks A. In consistency in the management of patients with hepatocellular carcinoma: the need for a strict protocol. Am Surg 2011; 77: 207-14.
66. Centre for Evidence Based Medicine. Oxford Centre for Evidence-based Medicine-Levels of Evidence (March 2009). Available:. Accessed 15 February 2011.
67. Kokudo N, Makuuchi M. Evidence-based clinical practice guidelines for hepatocellular carcinoma in Japan: the J-HCC guidelines. J Gastroenterol 2009; 44(Suppl. 19): 119-21.
68. Arii S, Sata M, Sakamoto M, et al. Management of hepatocellular carcinoma: report of consensus meeting in the 45th annual meeting of the Japan Society of Hepatology (2009). Hepatol Res 2010; 40: 667-85.
69. Kudo M, Okanoue T, Japan Society of Hepatology. Management of hepatocellular carcinoma in Japan: consensus-based clinical practice manual proposed by the Japan Society of Hepatology. Oncology 2007; 72(Suppl. 1): 2-15.
70. Clavien PA, Lesurtel M, Bossuyt PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report. Lancet Oncol 2012; 13: e11-e22.
71. World Health Organization. Executive Summary of the National Cancer Control Programmes: Policies and Managerial Guidelines. Geneva, Switzerland: World Health Organization, 2002.
72. Venook AP, Papandreou C, Furuse J, de Guevara LL. The incidence and epidemiology of hepatocellular carcinoma: a global and regional perspective. Oncologist 2010; 15(Suppl. 4): 5-13.
73. Schütte K, Bornschein J, Malfertheiner P. Hepatocellular carcinoma-epidemiological trends and risk factors. Dig Dis 2009; 27: 80-92.
74. Wogan GN, Kensler TW, Groopman JD. Present and future directions of translational research on aflatoxin and hepatocellular carcinoma. A review. Food Addit Contam Part A Chem Anal Control Expo Risk Assess 2011; 1: 1-9.
75. Song PP, Tang W, Tamura S, et al. The management of hepatocellular carcinoma in Asia: a guideline combining quantitative and qualitative evaluation. Biosci Trends 2010; 4: 283-7.
76. Song PP, Wu Q, Huang Y. Multidisciplinary team and team oncology medicine research and development in China. Biosci Trends 2010; 4: 151-60.